Medical/Pharmaceuticals
Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...
2026-09-13 14:59
4223
POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today a...
2026-09-10 20:00
2769
TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection
— Phase IIb multicenter trial initiated, bringing this potential life-changing therapy closer to patients — SUZHOU, China, Sept. 10, 2026 /PRNewswire/ -- TenNor Therapeutics, a near-commercial-stage biotechnology company, today announced positive topline results from a Phase IIa proof-of-concept...
2026-09-10 19:30
2739
Yuyu Pharma CEO Robert Wonsang Yu Launches "Robert's YUniverse" Podcast
SEOUL, South Korea, Sept. 9, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of
Yuyu Pharma, has launched"Robert's YUniverse
2026-09-09 21:00
4841
Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigati...
2026-09-09 20:25
2759
Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its su...
2026-09-09 20:00
2222
Daesang Targets Global Pharmaceutical Amino Acid Market, Building on 70 Years of Fermentation Technology
* Leverages fermentation know-how developed through MIWON to expand beyond general-purpose amino acids into high-value pharmaceutical materials * Acquires Germany-based AMINO GmbH, gaining purification technology, European regulatory expertise, and a global customer network SEOUL, South Kore...
2026-09-09 20:00
3722
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
* Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer * Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth q...
2026-09-09 19:12
2677
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit
HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developi...
2026-09-09 18:00
1924
Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026
Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and preci...
2026-09-08 21:00
3066
Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ...
2026-09-08 20:20
1988
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. * HBM9378/WIN378 produc...
2026-09-08 20:17
2356
/C O R R E C T I O N -- GCCL/
In the news release, "GCCL Strengthens Asia-Pacific Presence at Asia Bio Partnering Forum 2026," issued on September 8, 2026 by GCCL over PR Newswire, we are advised by the company that the name "Yoo-Hwa Choi" should read "Yuhwa Choi" throughout the release, as originally issued inadvertently. Co...
2026-09-08 16:05
2677
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. SHANGHAI, Sept. 7, 2026 /PRNewswire/ -- On September 7, 2026, Shanghai, Cell Stem Cell published online clini...
2026-09-08 08:00
1975
Ministry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio
– 5,600 participants from 19 countries discuss global bio innovation and the path forward – – Strengthened global regulatory cooperation, with a total of 23 meetings held with overseas regulators and industry, including 5 regulatory cooperation meetings – SEOUL, South Korea, Sept. 7, 2026 /PRNe...
2026-09-07 20:00
3333
Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
* First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). * First Universal Consensus Across Six Independently-De...
2026-09-07 17:42
3016
CelluPro Receives EXCiPACT™ Certification for GMP-grade Cell Culture Media Manufacturing, Strengthening Global Biomanufacturing Supply Capabilities
YANTAI, China, Sept. 7, 2026 /PRNewswire/ -- CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achievedEXCiPACT™ GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), becoming the first Chinese cell culture media supplier to r...
2026-09-07 14:00
1961
Rznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids Research
SEONGNAM, South Korea, Sept. 6, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in the high-efficiency production of circular RNA (circRNA) – a rapidly emerging modality ...
2026-09-07 12:36
2140
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today ann...
2026-09-07 08:46
2447
Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Robust neutralizing a...
2026-09-07 07:07
2586
Week's Top Stories
Most Reposted
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 295 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 284 media titles]
2026-10-15 10:00SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 282 media titles]
2026-10-15 12:59
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 273 media titles]
2026-10-21 15:00
Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
29152
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
18894